TMEFF2 promoter hypermethylation is an unfavorable prognostic marker in gliomas

Tytuł:: TMEFF2 promoter hypermethylation is an unfavorable prognostic marker in gliomas
Autorzy:: Sidi Xie
Yunxiao Zhang
Tao Peng
Jinglin Guo
Yongfu Cao
Jing Guo
Xiaofeng Shi
Yaqin Li
Yawei Liu
Songtao Qi
Hai Wang
Temat:: TMEFF2
Glioma
DNA methylation
IDH1
Prognosis
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282
Cytology
QH573-671
Źródło:: Cancer Cell International, Vol 21, Iss 1, Pp 1-11 (2021)
Wydawca:: BMC, 2021.
Rok publikacji:: 2021
Kolekcja:: LCC:Neoplasms. Tumors. Oncology. Including cancer and carcinogens
LCC:Cytology
Typ dokumentu:: article
Opis pliku:: electronic resource
Język:: English
ISSN:: 1475-2867
Relacje:: https://doaj.org/toc/1475-2867
DOI:: 10.1186/s12935-021-01818-x
Dostęp URL:: https://doaj.org/article/a534654d33b843f8b47d1289ed2dcb93 Link otwiera się w nowym oknie
Numer akcesji:: edsdoj.534654d33b843f8b47d1289ed2dcb93
: Czasopismo naukowe

Pełny tekst

Abstract Background Transmembrane protein with EGF-like and two follistatin-like domains 2 (TMEFF2) is a transmembrane protein in the tomoregulin family. Little research has been performed to determine whether TMEFF2 methylation is a prognostic marker in adult diffuse gliomas. Methods In this study, we investigated TMEFF2 expression in surgical glioma tissue samples. In addition, we conducted bisulfite amplicon sequencing (BSAS) and methylation-specific PCR (MSP) to evaluate TMEFF2 methylation in glioblastoma (GBM) cells. Subsequently, we investigated the biological function of TMEFF2 in GBM cells. Moreover, we explored the prognostic significance of TMEFF2 in gliomas by analysing a cohort dataset from TCGA. Results Immunohistochemistry analysis of 75 paired glioma tumour and peritumoural tissues demonstrated that glioma tumour tissues expressed lower TMEFF2 levels than peritumoural tissues (P

Zaloguj się, aby uzyskać dostęp do pełnego tekstu.

Informacja